Agios Financial Statements From 2010 to 2024

AGIO Stock  USD 31.67  0.14  0.44%   
Agios Pharm financial statements provide useful quarterly and yearly information to potential Agios Pharm investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Agios Pharm financial statements helps investors assess Agios Pharm's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Agios Pharm's valuation are summarized below:
Gross Profit
12.5 M
Market Capitalization
1.8 B
Enterprise Value Revenue
35.5852
Revenue
26.8 M
Earnings Share
(6.33)
We have found one hundred twenty available fundamental signals for Agios Pharm, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to validate Agios Pharm's prevailing fundamentals against the trend between 2010 and 2024 to make sure the company can sustain itself down the road. As of the 25th of April 2024, Market Cap is likely to grow to about 1.6 B. Also, Enterprise Value is likely to grow to about 1.5 B

Agios Pharm Total Revenue

25.48 Million

Check Agios Pharm financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Agios main balance sheet or income statement drivers, such as Depreciation And Amortization of 7 M, Interest Expense of 15.4 M or Selling General Administrative of 81.2 M, as well as many exotic indicators such as Price To Sales Ratio of 32.17, Dividend Yield of 0.015 or PTB Ratio of 1.45. Agios financial statements analysis is a perfect complement when working with Agios Pharm Valuation or Volatility modules.
  
This module can also supplement Agios Pharm's financial leverage analysis and stock options assessment as well as various Agios Pharm Technical models . Check out the analysis of Agios Pharm Correlation against competitors.
To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.

Agios Pharm Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets752.6 M937.1 M656.1 M
Slightly volatile
Other Current Liabilities29.6 M43.2 M25.3 M
Slightly volatile
Total Current Liabilities75.2 M68 M67.5 M
Slightly volatile
Total Stockholder Equity564.7 M811 M486.8 M
Slightly volatile
Other Liabilities3.6 M3.8 M67 M
Pretty Stable
Property Plant And Equipment Net52.5 M69.8 M45 M
Slightly volatile
Current Deferred Revenue11.9 M12.6 M45 M
Pretty Stable
Accounts Payable15.9 M9.8 M13.8 M
Slightly volatile
Cash83.8 M88.2 M230.5 M
Very volatile
Non Current Assets Total178.4 M103.3 M152.7 M
Slightly volatile
Other Assets4.8 M4.5 M1.8 M
Slightly volatile
Cash And Short Term Investments637.5 M776.9 M556.7 M
Slightly volatile
Common Stock Total Equity49.5 K81.7 K44.9 K
Slightly volatile
Common Stock Shares Outstanding48.8 M55.7 M43.2 M
Slightly volatile
Short Term Investments428.3 M688.7 M370.1 M
Slightly volatile
Liabilities And Stockholders Equity752.6 M937.1 M656.1 M
Slightly volatile
Non Current Liabilities Total112.7 M58.1 M101.8 M
Slightly volatile
Other Stockholder Equity1.2 B1.6 BB
Slightly volatile
Total Liabilities187.9 M126.1 M169.3 M
Slightly volatile
Property Plant And Equipment Gross128.1 M122 M45.6 M
Slightly volatile
Total Current Assets574.2 M833.8 M503.3 M
Slightly volatile
Common Stock51.8 K72 K44.5 K
Slightly volatile
Property Plant Equipment21.1 M26.4 M18.7 M
Slightly volatile
Net Tangible Assets633.1 M1.3 B536.7 M
Slightly volatile
Net Receivables2.7 M2.8 M6.8 M
Pretty Stable
Capital Surpluse1.7 B2.7 B1.3 B
Slightly volatile
Deferred Long Term Liabilities19.2 M20.2 M39.9 M
Pretty Stable
Long Term Investments28 M29.4 M105.1 M
Slightly volatile
Non Current Liabilities Other1.1 M1.2 M60.5 M
Pretty Stable
Net Invested Capital833.9 M811 M584.6 M
Slightly volatile
Net Working Capital702.8 M765.9 M508.5 M
Slightly volatile
Capital Stock75 K72 K63.2 K
Slightly volatile
Short and Long Term Debt Total75.8 M72 M104.8 M
Slightly volatile
Long Term Debt Total538.4 K605.7 K659.5 K
Slightly volatile
Capital Lease Obligations75.8 M72 M104.8 M
Slightly volatile

Agios Pharm Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense15.4 M14.7 M6.9 M
Slightly volatile
Selling General Administrative81.2 M119.9 M69.9 M
Slightly volatile
Total Revenue25.5 M26.8 M54.3 M
Pretty Stable
Other Operating Expenses321.8 M418.3 M277.6 M
Slightly volatile
Research Development239.2 M288.9 M206.5 M
Slightly volatile
Cost Of RevenueM9.5 M66.8 M
Slightly volatile
Total Operating Expenses320.4 M408.8 M276.4 M
Slightly volatile
Preferred Stock And Other Adjustments3.3 M3.7 M4.1 M
Slightly volatile
Non Operating Income Net Other35.5 M33.8 M11.2 M
Slightly volatile
Interest Income35 M33.3 MM
Slightly volatile
Reconciled Depreciation8.8 M6.6 M7.3 M
Slightly volatile
Discontinued Operations1.6 B1.8 B1.9 B
Slightly volatile

Agios Pharm Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation42.8 M44.8 M36.6 M
Slightly volatile
Begin Period Cash Flow112.4 M139.3 M101.3 M
Slightly volatile
Depreciation5.9 M6.6 M5.1 M
Slightly volatile
Capital Expenditures949 K999 KM
Pretty Stable
End Period Cash Flow113.3 M88.2 M104.7 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio32.1746.205143.7476
Slightly volatile
Dividend Yield0.0150.01690.0184
Slightly volatile
PTB Ratio1.451.52816.1297
Slightly volatile
Days Sales Outstanding36.2738.237737.7715
Slightly volatile
Book Value Per Share8.4114.57329.8497
Slightly volatile
Stock Based Compensation To Revenue1.751.66890.9811
Slightly volatile
PB Ratio1.451.52816.1297
Slightly volatile
EV To Sales28.6645.600839.4009
Slightly volatile
Inventory Turnover0.70.49821.1598
Slightly volatile
Days Of Inventory On Hand938733653
Slightly volatile
Payables Turnover1.020.97180.2717
Slightly volatile
Sales General And Administrative To Revenue1.561.491.062
Slightly volatile
Research And Ddevelopement To Revenue11.3110.77076.0549
Slightly volatile
Cash Per Share11.0813.960613.2502
Slightly volatile
Payout Ratio0.01860.02090.0228
Slightly volatile
Days Payables Outstanding3573763.8 K
Slightly volatile
Current Ratio12.8812.27047.7089
Slightly volatile
Tangible Book Value Per Share8.4114.57329.8497
Slightly volatile
Receivables Turnover13.679.545620.3612
Slightly volatile
Graham Number27.045.546631.5749
Slightly volatile
Shareholders Equity Per Share8.4114.57329.8497
Slightly volatile
Graham Net Net7.911.9049.2289
Slightly volatile
Revenue Per Share0.460.4821.2563
Pretty Stable
Operating Cycle1.1 K771805
Slightly volatile
Price Book Value Ratio1.451.52816.1297
Slightly volatile
Days Of Payables Outstanding3573763.8 K
Slightly volatile
Dividend Payout Ratio0.01860.02090.0228
Slightly volatile
Ebt Per Ebit1.050.89940.9586
Slightly volatile
Company Equity Multiplier1.831.15551.7699
Slightly volatile
Long Term Debt To Capitalization0.120.06570.129
Slightly volatile
Quick Ratio7.2611.47438.5923
Slightly volatile
Cash Ratio1.231.2983.214
Pretty Stable
Days Of Inventory Outstanding938733653
Slightly volatile
Days Of Sales Outstanding36.2738.237737.7715
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.131.00341.0421
Pretty Stable
Price To Book Ratio1.451.52816.1297
Slightly volatile
Fixed Asset Turnover0.370.38433.4878
Slightly volatile
Price Sales Ratio32.1746.205143.7476
Slightly volatile
Asset Turnover0.02720.02860.1034
Slightly volatile
Gross Profit Margin0.990.64570.9492
Slightly volatile
Price Fair Value1.451.52816.1297
Slightly volatile

Agios Pharm Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.6 B1.2 B2.1 B
Very volatile
Enterprise Value1.5 B1.2 BB
Pretty Stable

Agios Fundamental Market Drivers

Forward Price Earnings2.4655
Cash And Short Term Investments776.9 M

Agios Upcoming Events

22nd of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
22nd of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Agios Pharm Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Agios Pharm income statement, its balance sheet, and the statement of cash flows. Agios Pharm investors use historical funamental indicators, such as Agios Pharm's revenue or net income, to determine how well the company is positioned to perform in the future. Although Agios Pharm investors may use each financial statement separately, they are all related. The changes in Agios Pharm's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Agios Pharm's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Agios Pharm Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Agios Pharm. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue12.6 M11.9 M
Total Revenue26.8 M25.5 M
Cost Of Revenue9.5 MM
Stock Based Compensation To Revenue 1.67  1.75 
Sales General And Administrative To Revenue 1.49  1.56 
Research And Ddevelopement To Revenue 10.77  11.31 
Capex To Revenue(0.04)(0.04)
Revenue Per Share 0.48  0.46 
Ebit Per Revenue(14.60)(13.87)

Pair Trading with Agios Pharm

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Agios Pharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Agios Pharm will appreciate offsetting losses from the drop in the long position's value.

Moving together with Agios Stock

  0.83VKTX Viking Therapeutics Potential GrowthPairCorr
  0.65ELEV Elevation Oncology Earnings Call This WeekPairCorr

Moving against Agios Stock

  0.62GILD Gilead Sciences Earnings Call TodayPairCorr
The ability to find closely correlated positions to Agios Pharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Agios Pharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Agios Pharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Agios Pharm to buy it.
The correlation of Agios Pharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Agios Pharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Agios Pharm moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Agios Pharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Agios Pharm offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Agios Pharm's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Agios Pharm Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Agios Pharm Stock:
Check out the analysis of Agios Pharm Correlation against competitors.
To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.
You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Complementary Tools for Agios Stock analysis

When running Agios Pharm's price analysis, check to measure Agios Pharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Agios Pharm is operating at the current time. Most of Agios Pharm's value examination focuses on studying past and present price action to predict the probability of Agios Pharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Agios Pharm's price. Additionally, you may evaluate how the addition of Agios Pharm to your portfolios can decrease your overall portfolio volatility.
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Is Agios Pharm's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agios Pharm. If investors know Agios will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agios Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(6.33)
Revenue Per Share
0.482
Quarterly Revenue Growth
0.648
Return On Assets
(0.22)
Return On Equity
(0.37)
The market value of Agios Pharm is measured differently than its book value, which is the value of Agios that is recorded on the company's balance sheet. Investors also form their own opinion of Agios Pharm's value that differs from its market value or its book value, called intrinsic value, which is Agios Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agios Pharm's market value can be influenced by many factors that don't directly affect Agios Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agios Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Agios Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agios Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.